1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on July 27, 2024

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
SNY

CNW Group

9 hours ago

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
SNY

Zacks

10 hours ago

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News

SNY

Argus Research

13 hours ago

Analyst Report: Sanofi SA

SNY

Argus Research

13 hours ago

Market Digest: SNY, CMCSA, CMG, KLAC, KMB, RCL, UPS, AZN, MSCI, TSLA

AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
SNY

Investor's Business Daily

a day ago

AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment

SNY

Morningstar Research

a day ago

Analyst Report: Sanofi

Sanofi (SNY) Q2 2024 Earnings Call Transcript
SNY

Motley Fool

a day ago

Sanofi (SNY) Q2 2024 Earnings Call Transcript

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season
SNY

CNW Group

a day ago

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season

Press Release: Online availability of Sanofi’s half-year financial report for 2024
SNY

GlobeNewswire

a day ago

Press Release: Online availability of Sanofi’s half-year financial report for 2024

Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
SNY

Zacks

a day ago

Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
SNY

Benzinga

2 days ago

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand

Sanofi’s immunology bet starts to pay off
SNY

BioPharma Dive

2 days ago

Sanofi’s immunology bet starts to pay off

SNY

MT Newswires

2 days ago

Sanofi's Q2 Earnings Fall, Sales Increase

Sanofi lifts 2024 profit forecast on strength in Dupixent, new drugs
SNY

Reuters

2 days ago

Sanofi lifts 2024 profit forecast on strength in Dupixent, new drugs

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
SNY

GlobeNewswire

2 days ago

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
SNY

Zacks

2 days ago

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
SNY

Benzinga

3 days ago

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
SNY

Zacks

3 days ago

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
SNY

Zacks

3 days ago

Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?

Analysis-Drug giants eye China for deals despite growing Sino-US tensions
SNY

Reuters

4 days ago

Analysis-Drug giants eye China for deals despite growing Sino-US tensions

Sanofi: Information concerning the total number of voting rights and shares – June 2024
SNY

GlobeNewswire

4 days ago

Sanofi: Information concerning the total number of voting rights and shares – June 2024

SNY

MT Newswires

8 days ago

Market Chatter: Advent International, PAI Partners Among First-Round Bidders for Sanofi's Consumer Health Division

Sanofi’s ALTUVIIIO shows promise in paediatric haemophilia A treatment trial
SNY

Clinical Trials Arena

9 days ago

Sanofi’s ALTUVIIIO shows promise in paediatric haemophilia A treatment trial

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
SNY

GlobeNewswire

9 days ago

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Sanofi’s Consumer Arm Said to Draw Bids From Advent, PAI, CD&R
SNY

Bloomberg

10 days ago

Sanofi’s Consumer Arm Said to Draw Bids From Advent, PAI, CD&R

Three Euronext Paris Dividend Stocks With Yields From 3% To 4%
SNY

Simply Wall St.

12 days ago

Three Euronext Paris Dividend Stocks With Yields From 3% To 4%

SNY

MT Newswires

14 days ago

Market Chatter: Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale

Banks Plan €6 Billion Debt Financing for Sanofi Consumer Sale
SNY

Bloomberg

14 days ago

Banks Plan €6 Billion Debt Financing for Sanofi Consumer Sale

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
SNY

Zacks

15 days ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

FTC plans to sue top 3 PBMs over insulin prices: WSJ
SNY

Yahoo Finance Video

16 days ago

FTC plans to sue top 3 PBMs over insulin prices: WSJ

FTC to Sue Drug Managers Over Insulin Prices
SNY

The Wall Street Journal

16 days ago

FTC to Sue Drug Managers Over Insulin Prices

Sanofi ships U.S. influenza vaccines for the 2024/25 season
SNY

PR Newswire

16 days ago

Sanofi ships U.S. influenza vaccines for the 2024/25 season

FTC Chair Khan slams PBMs for higher drug prices in an interim report on the industry
SNY

Yahoo Finance

17 days ago

FTC Chair Khan slams PBMs for higher drug prices in an interim report on the industry

Why Kymera Therapeutics Stock Is Soaring Today
SNY

Motley Fool

17 days ago

Why Kymera Therapeutics Stock Is Soaring Today

SNY

Investing.com

17 days ago

Kymera Therapeutics soars as Sanofi expands phase 2 trials

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
SNY

Investopedia

17 days ago

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
SNY

Zacks

17 days ago

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

SNY

MT Newswires

18 days ago

Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
SNY

Zacks

19 days ago

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
SNY

Zacks

21 days ago

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

Dupixent “addresses current gap” in COPD biologics landscape
SNY

Pharmaceutical Technology

21 days ago

Dupixent “addresses current gap” in COPD biologics landscape

French State Investment Firm Eyes Stake in Sanofi Consumer Unit
SNY

Bloomberg

23 days ago

French State Investment Firm Eyes Stake in Sanofi Consumer Unit

Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
SNY

Bloomberg

23 days ago

Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit

SNY

MT Newswires

23 days ago

Update: Market Chatter: Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division

SNY

MT Newswires

23 days ago

Market Chatter: Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
SNY

Benzinga

23 days ago

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
SNY

Zacks

24 days ago

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

SNY

Argus Research

24 days ago

Analyst Report: Sanofi SA

SNY

Argus Research

24 days ago

Market Digest: SNY

EMA approves Sanofi’s Dupixent for COPD treatment in adults
SNY

Pharmaceutical Technology

24 days ago

EMA approves Sanofi’s Dupixent for COPD treatment in adults

SNY

MT Newswires

24 days ago

Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits

SNY

MT Newswires

24 days ago

Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
SNY

GlobeNewswire

24 days ago

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

SNY

MT Newswires

25 days ago

Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
SNY

Benzinga

25 days ago

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant

Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
SNY

Bloomberg

25 days ago

Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons

SNY

MT Newswires

25 days ago

Sector Update: Health Care Stocks Mixed Premarket Monday

Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
SNY

Insider Monkey

a month ago

Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)

Sanofi reports findings from Phase II relapsing MS treatment trial
SNY

Clinical Trials Arena

a month ago

Sanofi reports findings from Phase II relapsing MS treatment trial

SNY

MT Newswires

a month ago

Market Chatter: Sanofi Eyes Up to $1.61 Billion Investment at German Production Site

Sanofi eyes German insulin investment of up to $1.6 billion, source says
SNY

Reuters

a month ago

Sanofi eyes German insulin investment of up to $1.6 billion, source says

Where Will Novavax Be in 1 Year?
SNY

Motley Fool

a month ago

Where Will Novavax Be in 1 Year?

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
SNY

BioPharma Dive

a month ago

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
SNY

Simply Wall St.

a month ago

3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%

Formation Bio secures $372m funds for AI-driven drug platform
SNY

Pharmaceutical Technology

a month ago

Formation Bio secures $372m funds for AI-driven drug platform

Sanofi reports positive data from Phase III EoE treatment trial
SNY

Clinical Trials Arena

a month ago

Sanofi reports positive data from Phase III EoE treatment trial

SNY

MT Newswires

a month ago

Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study

SNY

MT Newswires

a month ago

Vigil Neuroscience Receives $40 Million Investment From Sanofi

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
SNY

GlobeNewswire

a month ago

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
SNY

GlobeNewswire

a month ago

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

SNY

MT Newswires

a month ago

Sanofi-backed Drug Developer Formation Bio Raises $372 Million

Sanofi reports data from Phase II demyelinating polyneuropathy trial
SNY

Clinical Trials Arena

a month ago

Sanofi reports data from Phase II demyelinating polyneuropathy trial

Pharma M&A: The top high value deals in 2023
SNY

Pharmaceutical Technology

a month ago

Pharma M&A: The top high value deals in 2023

SNY

MT Newswires

a month ago

Sector Update: Health Care Stocks Ease Late Afternoon

SNY

MT Newswires

a month ago

Update: Sanofi Progresses on Consumer Health Separation; Sale, Spinoff Still on Table

SNY

MT Newswires

a month ago

Sector Update: Health Care Stocks Easing Tuesday Afternoon

Press Release: Availability of the Q2 2024 Aide-mémoire
SNY

GlobeNewswire

a month ago

Press Release: Availability of the Q2 2024 Aide-mémoire

SNY

MT Newswires

a month ago

Market Chatter: Sanofi Seeks Initial Bids for Consumer Health Division

Sanofi Seeks Initial Offers for Its $20 Billion Consumer Arm
SNY

Bloomberg

a month ago

Sanofi Seeks Initial Offers for Its $20 Billion Consumer Arm

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
SNY

Zacks

a month ago

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

Sanofi and Biovac partner to produce polio vaccines in Africa
SNY

Pharmaceutical Technology

a month ago

Sanofi and Biovac partner to produce polio vaccines in Africa

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
SNY

GlobeNewswire

a month ago

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
SNY

GlobeNewswire

a month ago

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?
SNY

TipRanks

a month ago

Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
SNY

GlobeNewswire

a month ago

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

The secrets of success with Paul Hudson, CEO of Sanofi, the leader who’s channeling AI to find the next pharma wonder drug
SNY

Fortune

a month ago

The secrets of success with Paul Hudson, CEO of Sanofi, the leader who’s channeling AI to find the next pharma wonder drug

Sanofi and Belharra forge $700m partnership for immunological diseases
SNY

Pharmaceutical Technology

a month ago

Sanofi and Belharra forge $700m partnership for immunological diseases

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
SNY

BioPharma Dive

a month ago

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
SNY

Zacks

a month ago

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

SNY

MT Newswires

a month ago

Innate Pharma Reports 'Promising and Durable' Results From Phase 1/2 Monotherapy Targeting Blood Cancers

Is It Too Late to Buy Novavax Stock?
SNY

Motley Fool

a month ago

Is It Too Late to Buy Novavax Stock?

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
SNY

Investor's Business Daily

a month ago

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

Exploring Three Top Dividend Stocks On Euronext Paris
SNY

Simply Wall St.

a month ago

Exploring Three Top Dividend Stocks On Euronext Paris

Sanofi: Information concerning the total number of voting rights and shares – May 2024
SNY

GlobeNewswire

a month ago

Sanofi: Information concerning the total number of voting rights and shares – May 2024

A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
SNY

Motley Fool

a month ago

A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge

Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
SNY

Zacks

a month ago

Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion

Is Sanofi SA (NASDAQ:SNY) the Best International Pharmaceutical Dividend Stock?
SNY

Insider Monkey

a month ago

Is Sanofi SA (NASDAQ:SNY) the Best International Pharmaceutical Dividend Stock?

SNY

MT Newswires

2 months ago

Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
SNY

Investor's Business Daily

2 months ago

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
SNY

Zacks

2 months ago

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

Share on Social Networks: